smoking 25 cigarettes a day (Office of Health Economics, 1969) is almost certainly untrue, but it may well deter some smokers from making the effort to give up smoking and encourage some ex-smokers to return to the habit.
Introduction
The treatnent of cardiac arrhythmias by direct-current countershock is now an established procedure since its introduction by Lown et al. (1962) . Brief general anaesthesia is necessary for electric cardioversion, which can be a painful procedure. For elective cardioversion of atrial fibrillation, especially in rheumatic heart disease, it is desirable to prepare patients by previous anticoagulation for two to three weeks to avoid risks of thromboembolism. In addition, it is customary to stop digitalis preparations for at least four days to safeguard against the risks of digitalis associated arrhythmias. It is usual to start maintenance quinidine therapy one to two days before an elective procedure in order to prevent a recurrence of the arrhythmia. A sedative may be given just before the procedure.
Since earlier reports on the value and simplicity of diazepam administered intravenously as a short-acting hypnotic for cardioversion (Nutter and Massumi, 1965; Kernohan, 1966) and its advantages compared with thiopentone (Muenster et al., 1967) , there have been several supplementary reports from various centres (Kernohan, 1967; Winters et al., 1968; Hendrix, 1969; Lebowitz, 1969; Turkel and Lemmert, 1969; Woodbridge, 1969 ) commenting on the safety and convenience of the method.
The ideal circumstances of previous preparation are not easily achieved in developing countries where pressure on bed space and professional manpower can be excessive. Accordingly, the experience of cardioversion with intravenous diazepam alone reported in this paper is relevant to clinics with humble facilities. In so doing we confirm that electrical cardioversion as an elective procedure can be simplified further with the involvement of minimum personnel and at outpatient or day admission arrangement. The technique we describe has its theoretical hazards. It is, however, based on a reasonable balance of risks in the circumstances prevailing in developing countries.
Methods and Results Fifty-three consecutive patients (25 males, 27 females) were treated with direct-current cardioversion. One patient was treated twice, another three times, totalling 56 procedures in all. Their age range was 8 to 66 years. The most frequent underlying heart diseases encountered were rheumatic heart disease and endomyocardial fibrosis. Cardioversion was also carried out in patients with "congestive cardiomyopathy," ischaemic heart disease, constrictive pericarditis (postoperative), atrial septal defect (postoperative), and lone atrial flutter, atrial fibrillation, and ventricular tachycardia ( Table I ). The types of arrhythmia treated are shown in Table II . As in the practice of Muenster et al. (1967) our patients received digitalis, the usual maintenance dose on the day of the countershock. We do not feel that the wait involved in withholding digitalis for elective cardioversion is merited unless there has been evidence of digitalis toxicity. While many authors (Nutter and Massumi, 1965; Kahler et al., 1967; Muenster et al., 1967; Winters et al. 1968) administered quinidine before conversion, we did not do so because we wished to avoid quinidine toxicity, especially as its use in maintaining sinus rhythm is still controversial. Gunning et al. (1970) found that quinidine had no significant effect in the maintenance of sinus rhythm in a controlled long-term trial after cardioversion.
We have had no adverse experience from a general avoidance of anticoagulation. However, the 1 % risk of systemic or pulmonary embolism following cardioversion of chronic atrial fibrillation, especially in rheumatic heart disease, is an avoidable complication with the use of previous anticoagulation (Lown, 1967) .
Persisting amnesia as a complication of intravenous diazepam has often been reported (Thornton and Clarke, 1970) . Dense amnesia generally lasts not more than 10 minutes, and it would be wise to have patients stay in hospital at least until their powers of memory return after treatment. The prolonged amnesia in one of our patients seems to have been an unusual reaction.
It is not the purpose of this paper to consider the long-term effect of electric shock therapy for cardiac arrhythmias. Even if sinus rhythm does not persist in the more chronic heart disorders, we regard as important the improvement in cardiac output by restoration of sinus rhythm in patients with atrial fibrillation and cardiac failure. We have described elsewhere (Somers et al., 1971) our experiences in the treatment of atrial arrhythmias in endomyocardial fibrosis. With the use of intravenous diazepam cardioversion can be readily mastered by the general physician at an outpatient service. In our practice one operator with an assistant controlling the cardioverter can manage the cardioversion witlh intravenous diazepam.
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The treatment of spasticity due to spinal cord and other neurological lesions has long been unsatisfactory. Intrathecal injections of phenol (Nathan, 1959) may produce significant improvement in some patients for several months, though the risks of increasing weakness in the lower limbs and interfering with bladder function are obvious disadvantages. Various problems attend the drug treatment of spasticity, many of the agents introduced being quite ineffective when given by mouth. Chlordiazepoxide and diazepam are probably the most helpful preparations in common use, but both are likely to make patients unacceptably drowsy when effectively reducing spasticity. These drugs probably exert their effect by acting on spinal interneurones (Cook and Nathan, 1967) but their tranquillizing effects suggest that modification of supraspinal influences may also be involved.
The basis for a more rational approach to the problem has been provided by recent studies of spinal cord pharmacology (Lancet, 1970) . Attention has been focused on gamma-aminobutyric acid, which depresses all types of spinal neurones (Curtis and Watkins, 1965) and inhibits monosynaptic and multisynaptic reflex activity in the experimental animal. A preliminary report by Birkmayer, Danielczynk, and Weiler (1967) Arlien-S0borg, Grynderup, and Henriksen (1970) and of Jones, Burke, Marosszeky, and Gillies (1970) , the latter a placebo-controlled trial in six patients.
Preliminary Study Six patients with severe spasticity in their lower limbs due to spinal cord disease (five with multiple sclerosis and one with severe residual spastic paraparesis after surgical removal of a dorsal neurofibroma) were admitted to this study. In each case baclofen was administered in a single intravenous injection of 25 mg and orally in doses of 10 mg thrice daily for 10 days. An attempt was made to monitor the effects of the intravenous injection by needle electromyography, but interpretation of the data so obtained was virtually impossible because of interference due to flexor spasms induced in the muscles sampled. However, a trend in favour of the drug was thought to be present and there was certainly an appreciable improvement in spasticity on clinical examination in each patient (Barwick and Hudgson, 1967) . This was also the subjective impression of all the patients, though one (a middle-aged woman with neurofibromatosis) was unable to tolerate the oral preparation for more than two days because of nautea and vomiting (she had previously reported nausea and vertigo during the intravenous injection). Another patient had three major epileptic seizures and developed a confusional state when she was on the oral preparation. However, the situation was complicated in her case by the fact that she had moderately severe cerebral demyelination with dementia as well as spinal cord disease in addition to a fever due to urinary tract infection.
Double-blind Trial
The formal double-blind cross-over trial of baclofen was begun in mid-1968 and at the time of closing the trial 23 patients had completed it. To standardize the conditions of the trial as much as possible it was decided to limit entry to patients with lower limb spasticity due to spinal cord disease. Of the 23 patients 18 were suffering from multiple sclerosis and were in remission, but with severe residual neurological deficits; two had myelopathies associated with cervical spondylosis; one had motor neurone disease with unusually severe spasticity in his lower limbs; one was a case of familial spastic paraplegia; and one woman had a slowly progressive spastic paraparesis of uncertain nature, possibly "spinal" multiple sclerosis. Their
